Switch theme
Sign up to access all valuation multiples
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.
1994
76K+
LTM Revenue $13.1B
LTM EBITDA $2.7B
$22.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
DaVita has a last 12-month revenue (LTM) of $13.1B and a last 12-month EBITDA of $2.7B.
In the most recent fiscal year, DaVita achieved revenue of $12.8B and an EBITDA of $2.7B.
DaVita expects next 12-month revenue of XXX and NTM EBITDA of XXX
See DaVita valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $13.1B | XXX | $12.8B | XXX | XXX | XXX |
| Gross Profit | $4.3B | XXX | $4.2B | XXX | XXX | XXX |
| Gross Margin | 33% | XXX | 33% | XXX | XXX | XXX |
| EBITDA | $2.7B | XXX | $2.7B | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 21% | XXX | XXX | XXX |
| EBIT | $2.0B | XXX | $2.0B | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $855M | XXX | $936M | XXX | XXX | XXX |
| Net Margin | 7% | XXX | 7% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $8.7B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, DaVita's stock price is $136.
DaVita has current market cap of $10.3B, and EV of $22.1B.
See DaVita trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $22.1B | $10.3B | XXX | XXX | XXX | XXX | $10.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, DaVita has market cap of $10.3B and EV of $22.1B.
DaVita's trades at 1.7x EV/Revenue multiple, and 8.1x EV/EBITDA.
Equity research analysts estimate DaVita's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
DaVita has a P/E ratio of 12.0x.
See valuation multiples for DaVita and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10.3B | XXX | $10.3B | XXX | XXX | XXX |
| EV (current) | $22.1B | XXX | $22.1B | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | 8.0x | XXX | 8.1x | XXX | XXX | XXX |
| EV/EBIT | 10.9x | XXX | 11.3x | XXX | XXX | XXX |
| EV/Gross Profit | 5.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 12.0x | XXX | 11.0x | XXX | XXX | XXX |
| EV/FCF | 20.1x | XXX | 15.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDaVita's last 12 month revenue growth is 4%
DaVita's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $30K for the same period.
DaVita's rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
DaVita's rule of X is 32% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for DaVita and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | 9% | XXX | XXX | XXX |
| Rule of 40 | 23% | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 32% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $30K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Athens Medical Centre | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
DaVita acquired XXX companies to date.
Last acquisition by DaVita was XXXXXXXX, XXXXX XXXXX XXXXXX . DaVita acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was DaVita founded? | DaVita was founded in 1994. |
| Where is DaVita headquartered? | DaVita is headquartered in United States of America. |
| How many employees does DaVita have? | As of today, DaVita has 76K+ employees. |
| Who is the CEO of DaVita? | DaVita's CEO is Mr. Javier J. Rodriguez. |
| Is DaVita publicy listed? | Yes, DaVita is a public company listed on NYS. |
| What is the stock symbol of DaVita? | DaVita trades under DVA ticker. |
| When did DaVita go public? | DaVita went public in 1995. |
| Who are competitors of DaVita? | Similar companies to DaVita include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health. |
| What is the current market cap of DaVita? | DaVita's current market cap is $10.3B |
| What is the current revenue of DaVita? | DaVita's last 12 months revenue is $13.1B. |
| What is the current revenue growth of DaVita? | DaVita revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of DaVita? | Current revenue multiple of DaVita is 1.7x. |
| Is DaVita profitable? | Yes, DaVita is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of DaVita? | DaVita's last 12 months EBITDA is $2.7B. |
| What is DaVita's EBITDA margin? | DaVita's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of DaVita? | Current EBITDA multiple of DaVita is 8.0x. |
| What is the current FCF of DaVita? | DaVita's last 12 months FCF is $1.1B. |
| What is DaVita's FCF margin? | DaVita's last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of DaVita? | Current FCF multiple of DaVita is 20.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
